Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenti-HPV-07 in HPV-associated oropharyngeal and cervical cancer
NCT06319963Phase 2Recruiting
- Sponsor
- TheraVectys
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Whole Cell Cancer Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of Lenti-HPV-07 in cervical carcinoma and human papillomavirus-positive oropharyngeal squamous cell carcinoma (2 arms), sponsored by TheraVectys. Primary endpoints: Safety and Tolerability at 12 months and Optimal Biological Dose at 28 days. Started Aug 2024; status: recruiting.
02
Drugs
Lenti-HPV-07
03
Conditions
cervical carcinomahuman papillomavirus-positive oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on NCT06319963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319963.